Aims: High dose 131I-meta iodobenzylguanidine (131I-mIBG) combined with radiosensitizing topotecan and peripheral blood stem cell support is a promising treatment regimen for children with neuroblastoma (NB). Here we present our first experiences, with particular focus on in vivo whole-body dosimetry and radiation exposure to family caregivers and hospital staff. Methods: Five children with relapsed or refractory NB were treated during 2012-2014. 131I-mIBG was administered in two fractions at two weeks apart, aiming for a total whole-body radiation-absorbed dose of 4 Gy. The 131I-mIBG activity for the 2nd administration was calculated on the basis of the measured whole-body dose following the 1st administration. Patients were isolated in a ...
Neuroblastoma, which derives from neural crest, is the most common extracranial solid cancer in chil...
Patients with newly diagnosed high-risk (HR) neuroblastoma (NBL) still have a poor outcome, despite ...
Results of treatment with 131-1-Metaiodobenzylguanidine (131-I-MIBG) in patients with resistant ...
Aims: High dose 131I-meta iodobenzylguanidine (131I-mIBG) combined with radiosensitizing topotecan a...
BACKGROUND: The prognosis of patients with advanced neuroblastoma (NB) remains poor. Major and early...
Introduction131I‐meta‐iodobenzylguanidine (131I‐MIBG) is effective in relapsed neuroblastoma. The Ch...
For years there has been no substantial improvement in survival rates of children with advanced ...
The purpose of our study was to determine the effect of tumor-targeted radiation in neuroblastoma by...
Background: Half the children with high-risk neuroblastoma die with widespread metastases. Molecular...
PURPOSE: We aimed to evaluate the use of a dose monitoring program for calculating and comparing the...
Purpose: The aims of this study were to estimate the whole - body absorbed - dose with the Dicentric...
BACKGROUND: Treatment modalities like targeted radiotherapy with (131)I-meta-iodobenzylguanidine ((1...
Aim of the study: Radiolabelled meta-iodobenzylguanidine (MIBG) is an effective option in treatment ...
OBJECTIVES: To evaluate the role of iodine-131 metoiodobenzylguanidine (iodine-131 MIBG) scanning in...
Purpose: To assess the effect of local radiation administered to primary disease sites in children w...
Neuroblastoma, which derives from neural crest, is the most common extracranial solid cancer in chil...
Patients with newly diagnosed high-risk (HR) neuroblastoma (NBL) still have a poor outcome, despite ...
Results of treatment with 131-1-Metaiodobenzylguanidine (131-I-MIBG) in patients with resistant ...
Aims: High dose 131I-meta iodobenzylguanidine (131I-mIBG) combined with radiosensitizing topotecan a...
BACKGROUND: The prognosis of patients with advanced neuroblastoma (NB) remains poor. Major and early...
Introduction131I‐meta‐iodobenzylguanidine (131I‐MIBG) is effective in relapsed neuroblastoma. The Ch...
For years there has been no substantial improvement in survival rates of children with advanced ...
The purpose of our study was to determine the effect of tumor-targeted radiation in neuroblastoma by...
Background: Half the children with high-risk neuroblastoma die with widespread metastases. Molecular...
PURPOSE: We aimed to evaluate the use of a dose monitoring program for calculating and comparing the...
Purpose: The aims of this study were to estimate the whole - body absorbed - dose with the Dicentric...
BACKGROUND: Treatment modalities like targeted radiotherapy with (131)I-meta-iodobenzylguanidine ((1...
Aim of the study: Radiolabelled meta-iodobenzylguanidine (MIBG) is an effective option in treatment ...
OBJECTIVES: To evaluate the role of iodine-131 metoiodobenzylguanidine (iodine-131 MIBG) scanning in...
Purpose: To assess the effect of local radiation administered to primary disease sites in children w...
Neuroblastoma, which derives from neural crest, is the most common extracranial solid cancer in chil...
Patients with newly diagnosed high-risk (HR) neuroblastoma (NBL) still have a poor outcome, despite ...
Results of treatment with 131-1-Metaiodobenzylguanidine (131-I-MIBG) in patients with resistant ...